Scinai Immunotherapeutics Licenses VAX-24 Flu Vaccine
Ticker: SCNI · Form: 6-K · Filed: Mar 24, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: licensing-agreement, vaccine-candidate, update
TL;DR
Scinai licensed its VAX-24 flu vaccine to a US company on Sept 26, 2024.
AI Summary
On September 26, 2024, Scinai Immunotherapeutics Ltd. granted exclusive global rights to its VAX-24 influenza vaccine candidate to an unaffiliated U.S. private company, referred to as the "Licensee." This 6-K filing provides an update on this licensing agreement, which was previously disclosed.
Why It Matters
This licensing agreement allows Scinai to potentially monetize its VAX-24 asset while focusing on other pipeline developments, impacting its future revenue streams and strategic direction.
Risk Assessment
Risk Level: low — This filing is an update on a previously disclosed licensing agreement and does not introduce new material risks.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant and licensor of VAX-24
- VAX-24 (product) — Influenza vaccine candidate licensed to Licensee
- Licensee (company) — Unaffiliated U.S. private company that received exclusive rights to VAX-24
- September 26, 2024 (date) — Date the license agreement was entered into
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to provide an update on the previously disclosed license agreement entered into on September 26, 2024, between Scinai Immunotherapeutics Ltd. and an unaffiliated U.S. private company for the VAX-24 influenza vaccine candidate.
Who is the counterparty to the license agreement for VAX-24?
The counterparty is an unaffiliated U.S. private company referred to as the "Licensee."
What rights were granted under the license agreement?
Scinai Immunotherapeutics Ltd. granted exclusive global rights to its VAX-24 influenza vaccine candidate to the Licensee.
When was the license agreement originally entered into?
The license agreement was entered into on September 26, 2024.
Does this filing indicate any new financial terms or milestones related to the VAX-24 license?
This filing does not specify any new financial terms or milestones; it serves as an update on the existence and nature of the previously disclosed licensing agreement.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 24, 2025 regarding Scinai Immunotherapeutics Ltd. (SCNI).